Welcome to our dedicated page for Inari Medical news (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.
Inari Medical, Inc. (NASDAQ: NARI) is a leading medical device company dedicated to developing innovative solutions for the interventional treatment of vascular thrombi and emboli. The company's mission centers on improving the lives of patients suffering from venous and other related diseases through the design and production of advanced medical devices.
Inari Medical's product portfolio includes several key devices:
- ClotTriever: Designed for the removal of clots from peripheral blood vessels, primarily treating patients with deep vein thrombosis (DVT).
- FlowTriever System: Used for the treatment of pulmonary embolism (PE).
- InThrill System: Aimed at treating small vessel thrombosis.
- LimFlow System: Another innovative solution recently added to their portfolio through acquisition.
The company operates extensively within the United States but also generates significant revenue from international markets. Inari Medical's dedication to clinical research and patient education is evident in their continuous efforts to generate high-quality clinical data to support their products.
In recent news, Inari Medical announced the PEERLESS II RCT, a major clinical study involving up to 1,200 patients. This study aims to influence global guidelines for treating intermediate-risk PE patients. Inari's fourth-quarter financial results showed a substantial revenue increase, driven by the strong adoption of their procedures, new product launches, and global commercial expansion. The company reported $132.1 million in revenue for Q4 2023, marking a 22.6% increase year-over-year.
Additionally, Inari Medical has undertaken significant legal action to protect its intellectual property. The company filed a patent infringement lawsuit against Imperative Care, Inc. and Truvic Medical, Inc., seeking injunctive relief and damages for infringement on eight of its patents.
Guided by principles such as putting patients first and fostering innovation, Inari Medical continues to advance its mission of establishing its treatments as the standard of care for venous thromboembolism and beyond.
Inari Medical (NASDAQ: NARI) announced positive follow-up results from its FLASH study, involving 230 patients treated with the FlowTriever system for pulmonary embolism (PE). The 30-day mortality rate was just 0.4%, significantly lower than the national average of 25.9% for high-risk patients. The study also reported a readmission rate of 6.7% versus nearly 25% nationally. Patients showed significant improvements in hemodynamic variables and symptoms of dyspnea. With over 60% of participants having no contraindications to lytics, FlowTriever is establishing itself as a frontline therapy for PE.
Inari Medical (NASDAQ: NARI) has appointed Kevin Strange as VP of Strategy and Business Development and Angela Ahmad as General Counsel. Strange brings over 15 years of medical device experience, including roles at Boston Scientific and Bank of America Merrill Lynch. Ahmad, with 20 years of corporate and securities expertise, previously served as Deputy General Counsel at CoreLogic. These appointments aim to strengthen Inari's corporate strategy and legal oversight, focusing on venous disease innovations.
Inari Medical, Inc. (NASDAQ: NARI) reported a remarkable third quarter for 2020, achieving a record revenue of $38.7 million, reflecting a 172% increase year-over-year and 52% growth sequentially. The company treated over 3,700 patients, significantly expanding its commercial operations. Gross profit reached $35.5 million with a gross margin of 91.7%. Net income stood at $6.5 million, or $0.13 per share. Despite these achievements, Inari Medical refrained from providing financial guidance for the remainder of 2020 due to COVID-19 uncertainties.
Inari Medical (NASDAQ: NARI) announced its participation in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020. The company specializes in developing innovative medical devices aimed at treating venous diseases, focusing on its mechanical thrombectomy systems, ClotTriever and FlowTriever, which are FDA-cleared for deep vein thrombosis and pulmonary embolism, respectively. Inari's mission is to transform patient care by providing effective treatments that eliminate the need for traditional thrombolytic drugs.
Inari Medical, Inc. (NASDAQ: NARI) will release its third quarter 2020 financial results on November 12, 2020, after market close. A conference call will take place the same day at 1:30 p.m. PT to discuss the results and recent developments. Inari specializes in developing minimally-invasive products for treating venous diseases, with its ClotTriever and FlowTriever systems FDA-approved for deep vein thrombosis and pulmonary embolism respectively.
Inari Medical, Inc. (NASDAQ: NARI) announced positive interim results from its FLASH study, which involved 230 patients with pulmonary embolism (PE) across 19 U.S. sites. The study's primary endpoint was met by 98.7% of patients, showcasing a significant reduction in major adverse events. The study aims to assess outcomes from FlowTriever treatment, demonstrating immediate hemodynamic improvements, including a 23 bpm average heart rate decline and a 7 mmHg drop in pulmonary artery pressure. These findings underscore Inari's commitment to innovating venous thromboembolism treatments.
Inari Medical, Inc. (NASDAQ: NARI) announced that the interim results from the FLASH study will be presented at TCT Connect. The study evaluates the effectiveness of the FlowTriever System for treating pulmonary embolism in real-world patients. The interim data involves 230 patients across 19 U.S. sites. This late-breaking presentation will take place on October 18, 2020, at 12:05 PM ET, led by Dr. Catalin Toma. FLASH aims to assess safety and major adverse events within 48 hours post-procedure, showcasing Inari's commitment to advancing treatment for venous diseases.
Inari Medical (NASDAQ: NARI) announced the promotion of Drew Hykes to Chief Operating Officer, effective September 1, 2020. Hykes, who joined Inari as Chief Commercial Officer in 2017, will now oversee Research, Product Development, Manufacturing, Operations, Quality, and Regulatory in addition to Commercial functions. CEO Bill Hoffman lauded Hykes for his significant contributions to commercial success and his commitment to the mission of improving patient lives. Inari is focused on developing minimally-invasive solutions for treating venous conditions, including the ClotTriever and FlowTriever systems.
Inari Medical, Inc. (NASDAQ: NARI), a medical device company focused on treating venous diseases, announced its participation in two upcoming investor conferences. The events include the 2020 Wells Fargo Virtual Healthcare Conference on September 10 at 10:00 a.m. ET and the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 16 at 5:00 p.m. ET. Interested parties can access a live and archived webcast through the Investor Relations section of Inari's website. The company specializes in developing minimally-invasive devices for thromboembolism treatment.
Inari Medical, Inc. (NASDAQ: NARI) will participate in the Canaccord Genuity 40th Annual Virtual Growth Conference, set for August 12 at 4:30 p.m. Eastern Time. Live and archived webcasts of the presentation will be available on their website. Inari focuses on treating venous diseases, specifically venous thromboembolism, using innovative catheter-based devices. The company’s FDA-cleared ClotTriever system addresses deep vein thrombosis, while the FlowTriever system is designed for pulmonary embolism treatment.
FAQ
What is the current stock price of Inari Medical (NARI)?
What is the market cap of Inari Medical (NARI)?
What does Inari Medical, Inc. specialize in?
What are the key products in Inari Medical's portfolio?
Where does Inari Medical generate most of its revenue?
What recent clinical study has Inari Medical announced?
How did Inari Medical perform financially in the fourth quarter of 2023?
What is Inari Medical's approach to innovation?
Who should investors contact for more information?
What legal actions has Inari Medical recently taken?
What are Inari Medical's guiding principles?
How can interested parties access Inari Medical's live events?
